244 related articles for article (PubMed ID: 36260948)
1. Current status and new developments in sphingosine-1-phosphate receptor antagonism: fingolimod and more.
Constantinescu V; Akgün K; Ziemssen T
Expert Opin Drug Metab Toxicol; 2022 Oct; 18(10):675-693. PubMed ID: 36260948
[TBL] [Abstract][Full Text] [Related]
2. Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives.
Bravo GÁ; Cedeño RR; Casadevall MP; Ramió-Torrentà L
Cells; 2022 Jun; 11(13):. PubMed ID: 35805142
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
Roy R; Alotaibi AA; Freedman MS
CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
[TBL] [Abstract][Full Text] [Related]
4. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis.
Chaudhry BZ; Cohen JA; Conway DS
Neurotherapeutics; 2017 Oct; 14(4):859-873. PubMed ID: 28812220
[TBL] [Abstract][Full Text] [Related]
5. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects.
Chun J; Giovannoni G; Hunter SF
Drugs; 2021 Feb; 81(2):207-231. PubMed ID: 33289881
[TBL] [Abstract][Full Text] [Related]
6. Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Corsten CEA; Huygens SA; Versteegh MM; Wokke BHA; Smets I; Smolders J
Mult Scler Relat Disord; 2023 Dec; 80():105100. PubMed ID: 37944195
[TBL] [Abstract][Full Text] [Related]
7. Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.
Comi G; Hartung HP; Bakshi R; Williams IM; Wiendl H
Drugs; 2017 Oct; 77(16):1755-1768. PubMed ID: 28905255
[TBL] [Abstract][Full Text] [Related]
8. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine-1-phosphate receptor modulators versus interferon beta for the treatment of relapsing-remitting multiple sclerosis: findings from randomized controlled trials.
Yang S; Li X; Wang J; Wang T; Xu Z; Gao H; Chen G
Neurol Sci; 2022 Jun; 43(6):3565-3581. PubMed ID: 35243548
[TBL] [Abstract][Full Text] [Related]
10. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.
Huwiler A; Zangemeister-Wittke U
Pharmacol Ther; 2018 May; 185():34-49. PubMed ID: 29127024
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Cohen JA; Chun J
Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
[TBL] [Abstract][Full Text] [Related]
12. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate receptor modulators in multiple sclerosis.
Subei AM; Cohen JA
CNS Drugs; 2015 Jul; 29(7):565-75. PubMed ID: 26239599
[TBL] [Abstract][Full Text] [Related]
14. S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review.
Constantinescu V; Haase R; Akgün K; Ziemssen T
Ther Adv Neurol Disord; 2022; 15():17562864221133163. PubMed ID: 36437849
[TBL] [Abstract][Full Text] [Related]
15. Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems.
Healy LM; Antel JP
Curr Drug Targets; 2016; 17(16):1841-1850. PubMed ID: 26424391
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Candido K; Soufi H; Bandyopadhyay M; Dasgupta S
Mini Rev Med Chem; 2016; 16(7):547-54. PubMed ID: 26156414
[TBL] [Abstract][Full Text] [Related]
17. The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Soliven B; Miron V; Chun J
Neurology; 2011 Feb; 76(8 Suppl 3):S9-14. PubMed ID: 21339490
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.
Groves A; Kihara Y; Chun J
J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
McGinley MP; Cohen JA
Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
[TBL] [Abstract][Full Text] [Related]
20. Ponesimod for the treatment of relapsing multiple sclerosis.
Baldin E; Lugaresi A
Expert Opin Pharmacother; 2020 Nov; 21(16):1955-1964. PubMed ID: 32808832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
